Publication for PTTG1 and TPX2

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	PTTG1	PTTG1 regulator of sister chromatid separation, securin	9232			[link]
hsa	TPX2	TPX2 microtubule nucleation factor	22974

Pubmed ID	Priority	Text
22535157	0.97	PTTG1 and TPX2 have been previously shown to lead to increased expression and/or activity of Aurora A kinase.
	0.92	PTTG1/securin (10.4-fold higher), HMMR (10.0-fold higher), TPX2 (9.5-fold higher), STK6/Aurora A (9.4-fold higher), and TTK (9.4-fold higher).
	0.90	PTTG1 and TPX2 are overexpressed along with Aurora A kinase in our specimens.
	0.88	PTTG1, TPX2, TTK, and UBE2C in ULMS (n = 8) compared with myometrium (n = 6) or leiomyoma (n = 6).
28638452	0.97	TPX2 increased polyploidy, multinucleation and DNA damage in cells, indicating mitotic progression errors in TPX2-depleted liver cancer cells that resulted in reduced MPS1, BUB1, BUB3, MAD1, MAD2, CDK1, securin, separase, cyclin B1, B2, Aurora A and Aurora B protein expression in TPX2-targeted cells.
	0.89	securin, separase, cyclin B1, B2, Aurora A and Aurora B proteins were downregulated in TPX2-targeted cells (Figure 9C).
	0.68	TPX2 arrested G2/M transition causes genomic instability events, such as DNA damage, multinuclearity and ploidy, and suppresses the tumorigenesis of HCC cells resulting in the disruption of the mitotic proteins Cyclin B, CDK1, Securin, Seprase, Aurora A and Aurora B, as well as the deregulation of the S phase proteins Cyclin A, Cyclin E and CDK2.
24067424	0.97	PTTG and TPX-2 which were similarly modulated in normal mammary epithelium (Fig. 2A) and mammary tumor tissues (Fig. 2B) are presented.
	0.81	Pttg and TPX-2.
30988807	0.97	TPX2, BUB1B, CDCA8, UBE2C, NDC80, RRM2, NCAPG, NCAPH, PTTG1, FAM64A, ANLN, KIF4A, CEP55, CENPF, KIF20A, ASPM and HJURP) showed worse OS time and RFS time (data not shown; P<0.05).
	0.94	TPX2, BUB1B, CDCA8, UBE2C, NDC80, RRM2, NCAPG, NCAPH, PTTG1, FAM64A, ANLN, KIF4A, CEP55, CENPF, KIF20A, ASPM and HJURP was significantly associated with overall survival and recurrence-free survival time (P<0.05).
23704896	0.97	TPX2, BIRC5, KIAA0101, SHCBP1, UBE2T, PTTG1, NUSAP1, DEPDC1, HELLS, CCNB1, KIF4A, and RRM2, that may be involved in tumorigenesis and in the processes of invasion and progression of disease.
24400072	0.96	TPX2, BUB1, GINS2, RACGAP1, FOXM1, UHRF1, MCM2, RASD2, FGF5, CDC25A, CCNE2, ESM1, TOP2A, CDC45L, AURKA, PRC1, KIFC1, PTTG1, AURKB, KIF23, KIF11, KIF20B, CENPE, ASPM, TTK, MAD2L1, NUF2, CDC20, CCNA2 and CCNB2, were highly expressed in CC1 MSCs compared to CC2 MSCs (Fig. 3C, Table 3).
27056899	0.96	TPX2, TOP2A, MAD2L1, CCNB1, CDC20 and PTTG1 that are involved in spindle assembly checkpoint (SAC) as well as DNA damage checkpoint genes.
23145101	0.95	TPX2, CCNA2, CCNB1 and B2, CDC20, CSK2, CDC2, CDKN3, CENPE, CD28 ,TOP2A, ORC1L, NUF2, CDK1, KIF2C, PTTG1 and TTK.
29572470	0.95	PTTG1, PRC1, CENPN, PPA1, CDC45, TPX2, and CLIC2 are most influential in PC1 and are involved in cell cycle, homeostasis pathways, and direct cell recognition.
29062989	0.94	PTTG1, CDC2, KIAA0101, DLG7, NUF2, S100P, TPX2, and IFI30.
29606879	0.93	securin, and separase), spindle pole organization (TPX2 and NDC80), and kinetochore attachment (Aurora A and Aurora B) decreased after DTL depletion in liver cancer cells.
31423162	0.92	pituitary tumor-transforming gene 1 protein (PTTG1), DNA topoisomerase 2alpha (TOP2A), targeting protein for Xklp2 (TPX2), ubiquitin-conjugating enzyme E2 C (UBE2C) and ZW10 interacting (ZWINT)] were considered hub genes and subjected to further analysis and validation.
	0.92	PTTG1, TOP2A, TPX2, UBE2C and ZWINT) that are closely associated with breast cancer were identified.
	0.63	PTTG1, TOP2A, TPX2, UBE2C and ZWINT) were present in MEblue.
20436289	0.91	TPX2 and securin levels are low in G1/S and increase as cells progress to G2.
	0.68	securin) and APCCdh1 (Aurora A, TPX2, Cdc20) substrates (Fig. 2E, Suppl.
31612029	0.91	PTTG1, (J) CDK4, (K) TPX2, (L) PRC1, (M) CKS2, (N) CDC45, (O) KPNA2, (P) NCAPG and (Q) UBE2S.
25743702	0.88	PTTG1, P = 0.019; ESPL1, P = 0.015; CCNB1, P = 0.018; BUB1, P = 0.023; TPX2, P = 0.032; and MCM2, P = 0.040, t-test) (Fig. 1a).
31981472	0.88	targeting protein for xklp2 (TPX2, OMIM:605917), TTK protein kinase (TTK, OMIM:604092), V-Myb avian myeloblastosis viral oncogene homolog-like 2 (MYBL2, OMIM:601415), pituitary tumor transforming gene 1 (PTTG1, OMIM:604147), DNA topoisomerase II alpha (TOP2A, OMIM:126430), centromere protein U (CENPU, OMIM:611511), and UBE2T( OMIM:610538).
21082037	0.79	PTTG1, ESPL1, TOP2A, NEK2, AURKA, TPX2, PLK1, etc.
23756599	0.73	Pttg1, Racgap1, Top2a, Tpx2, which are associated with the aggressive behaviour of various human tumors, including PAs, and proto-oncogenes such as Ect2, Kit, Kras, Lyn, Ret are up-regulated in rat adenomas.
29051608	0.71	PTTG1, FAM83D, KIF2C, NUMA1, KLHL21, KIF11, CKAP5, TPX2, NUF2, CENPF, NDC80, PBK, REEP4, ARL8A, MIS18BP1, SNX33, etc.).